Ariad Pharmaceuticals (NASDAQ:ARIA) gained approval from the Food and Drug Administration for its chronic myeloid leukemia drug Iclusig in mid-December. The drug is currently approved for patients who don't respond to treatment with Novartis' (NYSE:NVS) Gleevec, Tasigna, or Bristol-Myers Squibb's (NYSE:BMY) Sprycel. With FDA approval now complete, the big question mark hanging over Ariad in 2013 is whether its Iclusig launch will be successful. In this video, analyst Max Macaluso weighs in and highlights issues that investors need to watch this year.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.